The potential benefits of using NAT2 genotype‐informed phenotype to guide hydralazine therapy are to achieve effective blood pressure reduction in the setting of resistant hypertension and minimize the incidence of drug‐induced SLE. This evidence concerns the gene NAT2 and systemic lupus erythematosus.